Golden
LoginSign Up
Synlogic

Synlogic

A company developing therapeutic probiotics that alter the human gut microbiome to treat diseases.

Synologic is a clinical-stage biopharmaceutical company developing living medicines to treat a range of metabolic diseases, inflammatory diseases, and cancers. The technology platform uses synthetic biology to engineer beneficial bacteria, or probiotics, that alter the composition of the gut microbiome to restore proper metabolic functions. The populations of bacteria comprising the gut microbiome play a critical role in regulating the human immune system, metabolic function, brain health, and more. The company was founded in 2007 and is headquartered in Boston, Massachusetts.

Clinical programs

The majority of the company's drug candidates are in pre-clinical testing, although its lead drug candidate is in phase 2 trials. Synlogic calls its probiotics Synthetic Biotics. The pipeline as of July, 2nd, 2018:

Disease Targeted
Stage of Development
Partner

Hepatic encephalopathy

Phase 2

None

Immune oncology (three programs)

Pre-clinical

None

Inflammatory bowel disease

Pre-clinical

AbbVie

Liver disease

Screening

None

Maple Syrup urine disease

Pre-clinical

None

Organic acidemias

Pre-clinical

None

Phenylketonuria (PKU)

Pre-clinical

None

Urea cycle disorder

Phase 1

None

Partnerships

AbbVie

Ginkgo Bioworks

In December 2017 Synlogic and Ginkgo Bioworks announced a collaboration to use the latter's industrial scale organism engineering platform to discover new drug candidates.

Timeline

People

Name
Role
Related Golden topics

Further reading

Title
Author
Link
Type

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References